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Radiocontrast Induced Nephropathy
J. S. Lindholt
Department of Vascular Surgery, Rigshospitalet, Copenhagen, Denmark
In spite of improvements in chemical structure, contrast media assisted X-ray examination is still the third leading cause of
hospital-acquired acute renal failure. An increase 450% or 488mmol/L in S-creatinine is a clinically important acute
renal failure. The peak in S-creatinine occurs within 2±5 days after exposure. The frequency of oliguria, transient or
permanent haemodialysis is unknown.
The cause is a hypoxic tubular injury due to vasoconstriction with release of free oxygen radicals. Major risk factors are
prior renal insufficiency and diabetes mellitus. Minor risk factors are congestive heart disease, dehydration, hypotension,
hypoxia, amount of contrast, ionic and high osmolar contrast, repeated examinations at short intervals, abdominal
examination, and perhaps age, smoking, hypercholesterolaemia, and use of Non-Steroidal Anti inflammatory Drug.
Prevention seems possible by omission or reduction of contrast, ameliorating predisposing factors, saline hydration 24 h
before and after exposure, and 600 mg acetylcysteine orally twice daily 24 h before and after exposure. A three-day treatment
with 20 mg nitrendipine daily, starting 1 day before examination may also be preventive.
The present research is unfortunately characterised by small numbers, lack of clinical important renal failure, and lack of
long term results. The latter may be important after new data indicate that radiation may trigger a chronic oxidative process
through a similar pathway.
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Introduction
Contrast nephropathy (CN) is a well-recognised
complication of arteriographic procedures, but also of
intravenous urography and Computed tomography-
scans with use of intravenous contrast media.
The signs are mostly a mild detoriation of the renal
function with transient proteinuria and signs of tubu-
lar damage.1
The numbers of contrast media-enhanced examina-
tions are increasing. The annual sale of iodine for
contrast media now represents 60 million doses a
year worldwide. In spite of improvements in chemical
structure, contrast media-enhanced examinations are
still the third leading cause of hospital-acquired acute
renal failure.2
Several potential preventive possibilities seem to
exist. Consequently, a review of the causes and pre-
ventive strategies was made.
Methods and Material
The Pubmed database was searched for relevant
publications. The first search terms were `` Radiocon-
trast nephropathy and angiography and risk factors''
limited by English and procedures studied above 100
and after 1980. Unfortunately, relevant papers were
mostly from 1984±1996. The second search terms
were `` Radiocontrast nephropathy and angiography
and pathogenesis'' limited by English and after 1980.
The third search terms were `` Radiocontrast
nephropathy and prevention'' limited by English and
clinical controlled trial and after 1980.
Definitions and Manifestations
CN can be defined as an acute impairment of renal
function that follows exposure of radiocontrast
enhanced examination and for which alternative
explanations for renal impairment have been
eliminated.13
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The clinical presentation of CN is distinct, having a
temporal relation between the performance of the
contrast study in the high-risk patient and the onset
of an increase in S-creatinine levels within the next
24 h±5 days. S-creatinine values greater than 50% of
baseline, or rising by 88 mmol/L or more seem diag-
nostic. However, the definition varies (Table 1). The
peak S-creatinine level occurs within 3±5 days of the
contrast enhanced study. After the introduction of less
nephrotoxic contrast media, the frequencies of oli-
guria, transient and permanent dialysis are mostly
unknown. It was earlier reported to be approximately
in 25±30 and 10±20%, respectively,14±16 and with the
introduction of modern contrast agents probably
reduced. However, the long term prognosis or
whether radiological examinations without or with
signs of CN cause a progressive degenerative process
seems not have been described.
Monitoring S-creatinine is the most useful clinical
procedure in high-risk patients after angiography.13
However, S-creatinine is probably not the best param-
eter since the renal function must be severely
damaged before changes in S-creatinine is observed
(Fig. 1). Besides S-creatinine, impaired clearance can
also be studied by measuring carbamide, creatinine
clearance, urinary creatinine, osmolarity, albumin,
alanylamino-peptidase, N-acetyl-beta-glucosamini-
dase, and alpha-1-microglobulin.17,18
CN also have a high incidence of cortical contrast
retention that is detectable on non-enhanced com-
puted tomography.19
Pathogenesis
Low oxygen tension normally exists in the outer renal
medullar region, reflecting the sensitive regional oxy-
gen supply and a high local metabolic rate and oxygen
requirement, resulting from active salt reabsorption
by medullary thick ascending limbs of Henle's loop.
Contrast agents markedly aggravate this outer
medullary physiologic hypoxia3 because they cause
enhanced metabolic activity and oxygen consumption
as a result of osmotic diuresis and increased salt
delivery to the distal nephron because the regional
blood flow and the oxygen supply actually increase
in this area. It is believed that this may result from the
activation of various regulatory mediators of outer
medullary blood flow to ensure maximal regional
oxygen supply in the distal nephron. This local vaso-
motoric response seems to involve complex and
dynamic interactions between glomerular, tubular
and interstitial cells mainly caused by decreased pro-
duction of nitric oxide, a vasodilator, and increased
production of endothelin, a vasoconstrictor 10 times
more potent than angiotensin II, vasopression and
neuropeptide Y, making it the most potent endogen-
ous vasoactive substance known.4,5 The result of the
haemodynamic changes is hypoxia with following
oxidative stress and repair.
Adenosine, a renal vasoconstrictor is thought to
play a role in CN.6,7 Also, stimulation of the dopamine
receptors and angiotensin II seems to influence.3
One putative pathway might be generation of free
oxygen radicals.8 Kidney cells can produce various
free oxygen radicals,9 antioxidants have proven bene-
ficial in the treatment of experimental renal disease,10
and nephrotoxic agents can reduce the content of anti-
oxidants in the kidneys.11 However, radiation of cells
with 10 Gy has shown to lead to oxidative stress
through a similar pathway, and recently, Robbins
et al. found in an animal study, marked dose±response
Table 1. Various used definitions of contrast induced
nephropathy.
(1) An increase of greater than 50% in the S-creatinine level.
(2) An increase in S-creatinine of 88mmol/L or
(3) An increase in S-creatinine of 44 mmol/L or more.
(4) An increase in S-creatinine, at least 25% over baseline,
within 48 h of
(5) An increase in S-creatinine greater than 0.3 mg/dl (26.4mmol/L)
and greater than 20%, 1±7 days after radiological examination.
Clinical important acute renal failure.
Fig. 1. The relationship between S-creatinine and glomerular
filtration rate (GFR). (Medicinsk Kompendium, Munksgaard,
Copenhagen 1986).
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related signs of chronic oxidative DNA damage 24
weeks after radiation.12 Whether CN also causes a
chronic oxidative damage is unknown.
Contrast Agents
The type and volume of contrast used are correlated
with the risk of CN.14,15,23,25 Furthermore, abdominal
aortic,14,15 and cardiac examinations28,35 compared
with peripheral arteriography are associated with a
higher risk of CN.
The contrast agents are all watersoluble and build
of tri-iodobenzene devariates. According to the
structure, they are separated into whether they are
ionised, and whether the tri-iodobenzene is a mono-
mer or a dimer (consisting of two triiodbenzene cores).
Each agent is made with various iodid-concentrations,
and the osmolarity is proportional with this content.
Furthermore, the osmolarity depends upon the
number of particles in the solution. Consequently,
ionised monomere agents have three times as high
osmolarity as non-ionised monomere and ionised
dimere with the same iodid-concentration. Non-
ionised dimere have the lowest osmolarity. Various
examples of contrast agents are listed in Table 2.
As mentioned, the agents cause enhanced metabolic
activity and oxygen consumption as a result of
osmotic diuresis. Consequently, the osmolarity and
perhaps chemical structure of the agents must
influence the potential nephotoxicity.
In a randomised trial, 249 subjects with prior renal
insufficiency were randomised to receive high or low
osmolar contrast. S-creatinine rose by at least 25% in
6.8% given high and 3.8% given low osmolar contrast
(p40.05). Greater than 50% increase in S-creatinine
was seen in 3.4% with high osmolar contrast
(HOCM) and 1.5% with low osmolar contrast
(LOCM) (p40.05). Risk factors were prior renal insuf-
ficiency and diabetes mellitus, but not with type of
contrast.34 However, the sample size was obviously
not powered to detect such a relatively small
difference. In a large metaanalysis, 31 randomised
trials studying LOCM versus HOCM were used. The
pooled p-value was 0.02. Consequently, the difference
seems small. However, among 25 trials with available
data, the pooled odds ratio of a rise in S-creatinine
level of more than 44 mmol/L with LOCM was 0.61
(0.48±0.77) times that after HOCM. For patients with
existing renal failure, this odds ratio was 0.50
(0.36±0.68), while it was 0.75 (0.52±1.1, p40.05) in
patients without prior renal failure. Greater changes
in S-creatinine level occurred only in those with exist-
ing renal failure and were less common with LOCM
(OR: 0.44 (0.26±0.73). Consequently, the risk reduction
with LOCM is considerable, especially in cases with
existing renal failure.35
Today ionised monomeric contrast media has been
abounded. The non-ionic dimeric contrast media are
isoosmolar to plasma cause even fewer haemo-
dynamic side-effects and could in theory be less
toxic.2 Experimental studies have suggested that
non-ionic contrast agents are less nephrotoxic than
ionic contrast agents. However, in a large randomised
trial, Schwab et al. were unable to demonstrate a dif-
ference in the frequency of CN between patients
receiving a non-ionic contrast agent and those receiv-
ing an ionic contrast agent.33
However, in another randomised trial with 1196
patients with prophylactic hydration, the frequency
of clinical important CN was 7% in patients receiving
diatrizoate (ionic) compared to 3% patients receiving
iohexol (non-ionic) (p50.002). The differences in CN
between the two contrast groups were confined to
patients with prior renal insufficiency alone or com-
bined with diabetes. In a multivariate analysis, base-
line S-creatinine, male gender, diabetes, volume of
contrast agent, and prior renal insufficiency were
independently related to the risk of CN.28
Frequency and Major Risk Factors
Unfortunately, very few studies concerning frequency
and risk factors with an acceptable large study group
have been published after the introduction of the less
nephrotoxic modern contrast media. However, the
above mentioned randomised trial28 found the fre-
quency of clinical important CN was 3±7% depending
upon whether modern ionised or modern non-ionised
agents were used. Nevertheless, the pathogenesis
seems to be the same, and the lessons learned in the
past concerning risk factors must be expected to
persist. Irrespective of the exact frequency, two major
risk factors have been identified: pre-existing renal
disease and diabetes mellitus (Table 3). When renal
insufficiency defined as elevated S-creatinine and
Table 2. Contrast agents for intravascular use.
Ionised Non-ionised
Monomer Amidotrizoate Iobitridole
Diatrizoate (Abounded) Iohexole
Iomeprole
Iopamidole
Ioversole
Iopromide
Dimer Ioxaglinate Iodixanole
Iotrelane
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diabetes both coexists the risk of CN increases up to
10 times.13±15,20±24,28 Only a single large study have
been unable to find elevated S-creatinine as a risk
factor of CN.22
Minor and Potential Risk Factors
Congestive heart failure is also often associated with
CN, but with a lower risk than diabetes and elevated
Table 3. Studies concerning risk factors for contrast induced nephropathy.
Reference Contrast agent n Definition Risk factors Not risk factors
Parfrey20 N.A. 220 SCr4 25% DM with "SCr DM without "SCr
"SCr Dehydration
Taliercio21 Iopamidol 307 SCr4 88mmol/l DM Age
Diatrizoate Congestive heart failure Gender
Contrast volume None congestive heart dis.
Number of exam Hypertension
Hyperuricemia
Proteinuri
Use of diurectics
Use of betablockers
Use of digoxin
Moore22 Omnipaque 929 SCr4 44mmol/l DM "SCr
or Scr4 33% Furosemide, Liver disease
Atrophic disease Nephrotoxic drug
Age
Gender
Steroid
Ca-antagonist
Hypertension
Contrast volume
Lautin23 Diatrizoate 394 SCr4 26mmol/l DM with SCr No DM and no SCr
Ioxaglate Scr4 20% DM Age
Iohexol "Scr Gender
Gussenhoven24 Hexabrix 396 SCr4 10% DM Site of injection
Isopaque Age4 70 Antihypertensive drugs
Hypertension
Vol. contrast4 150 ml
"SCr
Paredero15 N.A 400 SCr4 88 mmol/l "SCr Normal Scr
or SCr450% Contrast volume DM
Abd. aortic studies Liver insufficiency
Congestive heart failure Hypertension
Low S-alubumin
Proteinuri
Hyperuricaemia
Use of diurectics
Use of betablockers
Use of digoxin
Gomes14 Isopaque 364 SCr488mmol/l "SCr Liver insufficiency
Conray 60 or SCr450% DM Hypertension
Vascoray Contrast volume Low S-albumin
Abd. aortic studies Proteinuri
Congestive heart failure Hyperuricaemia
Use of diurectics
Use of betablockers
Use of digoxin
Rich26 Diatrizoate 183 SCr444mmol/l "SCr Age
Iohexol DM Gender
Congestive heart failure None congestive heart dis.
Vol. Contrast 4200 ml Pulmonary disease
Low S-albumin535 g/l* Use of betablockers
S-Sodium 5135 mmol/l Use of digoxin
Use of ACE-inhibitors
Use of Calcium-antagonists
"SCr: Elevated S-creatinine. DM: Diabetes mellitus. SCr: Change in S-creatinine before and after examination. N/A: Not available.
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S-creatinine14,15,21,25 (Table 3). Due to the hypoxic com-
ponent in the pathogenesis, one ought to believe that
chronic obstructive pulmonary disease are associated
with CN. Apparently, it has not been investigated.
Both hypotension and hypertension has been reported
as a risk factor CN, while others could not.21,24,25
Antihypertensive and nephrotoxic drug medication
seems not to increase the risk of CN, neither does
hyperuricemia, liver or allergic diseases.22
Other studies found age to be a risk factor of
CN,14,15,27 while other have not.21,23,26 The male gen-
der is variably described associated with CN.23,28
Independent risk factors for CN have also been
reported to be S-albumin 535 g/L, S-sodium
5135 mmol/L.26
Furthermore, in a human clinical controlled study,
smoking and nicotine were accompanied by signifi-
cant acute changes in renal hemodynamics and
albuminuria. Consequently, smoking before contrast
radiation could increase the risk of CN.38
Finally, hypercholesterolaemia aggravated CN in an
animal study but human studies are missing.39 Major,
minor, and possible risk factors are summarised
in Table 4.
Prophylactic Possibilities
Omission
The most efficient prevention would of course be
avoiding contrast enhanced X-ray examination, for
example by using alternative imaging with ultrasound
or MR-angiography/urography. If not possible, use of
non-ionic dimere in low-osmolar concentrations
would be less nephrotoxic because of smaller osmotic
load and vasomotor alterations.40
Identification and ameliorating of
predisposing factors
According to the pathogenesis, predisposing factors
must be optimised as heart failure, and salt, water, and
blood depletion. Optimising of respiratory diseases,
oxygen supply in cases with habitual low saturation,
avoidance of non-steroidal anti-inflammatory agents
which inhibits prostacyclin production could in
theory lower the risk of renal medullary hypoxia.
Saline hydration
Eisenberg et al. reported in 1981, that 537 patients
undergoing angiography did not experience any
serious renal failure, and believed it was due to intra-
venous infusion 12±24 h before angiography.39 The
strategy and observation was followed by others,42,43
but apparently never tried in randomised trials
(hydration versus no hydration). In a randomised
trial, it was proven that hydration could be taken per
orally at home (1l over 10 h), and followed by 6 h of
intravenous hydration (0.45 normal saline solution at
300 ml/h) beginning just before contrast exposure.44
Recently, a major randomised trial showed showed
isotonic hydration was superior to half-isotonic
hydration, and thus indirectly that hydration
matters.36
Forced diuresis
In another randomised trial, patients were randomly
assigned to receive 0.45% saline alone for 12 h before
and after angiography, saline plus mannitol, or saline
plus furosemide. The mannitol and furosemide were
given just before angiography. In 11%, S-creatinine
increased more than 44 mmol/l compared with 28%
in the mannitol group, and 40% in the furosemide
group (p 0.05). The mean increase in S-creatinine
was significantly greater in the furosemide group
than in the saline group.45 Consequently, forced
diuresis cannot be recommended.
Haemodialysis
In a randomised trial performing hemodialysis or not
immediately after contrast exposure in 113 patients
with prior renal insufficiency, haemodialysis did not
diminish the rate of complications, including CN.46
Similar findings were observed on two other rando-
mised trials.47,48 The finding seems logical, since the
Table 4. Summary table of fisk factors for contrast induced
nephropathy.
Major risk factors
Prior renal insufficiency
Diabetes mellitus, especially insulin-dependent
Minor risk factors
Congestive heart disease
Dehydration
Hypotension
Hypoxia
Contrast amount used
Repeated contrast examinations at closely spaced intervals
Aortic, cardiac or renal examination
Possible minor risk factors
Age
Smoking
Hypercholesterolaemia
Non-steroid anti-inflammatory agents
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main exposure must occur while the contrast
enhanced examination occurs.
Renal vasodilators
Adenosine-inhibiting-renal vasodilators
Patients with diabetes or prior renal insufficiency
have a higher sensitivity of the renal vascular muscu-
lature to adenosine.31 However, in a clinical controlled
trial trial with 26 receiving 200 mg intravenous amino-
phylline, compared with 26 individually matched
controls for baseline creatinine, diabetes mellitus and
amount of contrast, there was no significant difference
between cases and controls. However, 18 patients with
prior renal impairment were randomised to receive a
continuous infusion of aminophylline or placebo
before and during the radiocontrast procedure. There
was a persistent deterioration in renal clearance in
those who received more than 135 ml of contrast
media, but it was not prevented by the use of adenso-
sine.49 However, the number of participants was
small, especially if the frequency of CN is taken into
account.
Another adenosine inhibitor, theophylline, have
been tested twice: First in 78 intensive care unit
patients who had 200 mg theophylline per 70 kg
body weight intravenously 30 min before examination
with more than 100 ml contrast medium. Despite the
large number of risk factors, S-creatinine concentra-
tions did not increase 24 and 48 h after the contrast
enhanced examination. The study design is obviously
debatable, but the results are nevertheless interesting.
However, they are in contrast to a study where
80 patients with prior renal insufficiency were ran-
domly assigned to receive either theophylline
(810 mg daily) or placebo together with hydration
started at least 24 h before and lasted until 24 h after
contrast media application. All received more than
100 ml. S-creatinine and creatinine clearance did not
change significantly in either group. An increase in
N-acetyl-beta-glucosaminidase excretion reached stat-
istical significance in the placebo group on days 2 and
3 after exposure. They concluded that adenosine play
a role in CN due to the increase in enzymuria. How-
ever, the GFR was preserved by hydration alone, and
the CN-frequency was very low.50
Fenoldopam
This newly available renal vasodilator was tested in 46
high risk patients with prior renal insufficiency with
and without coexisting diabetes mellitus, and com-
pared with a previously published cohort of similarly
at-risk patients. The frequency of CN, defined as an
increase in S-creatinine above 25%, 2 days after the
angiography was 13% in the group treated with fenol-
dopam, compared to an expected 38% (p50.05).51
Obviously, the control group is debatable, and rando-
mised trials are needed.
Prostaglandin E-1
One hundred and thirty patients with prior renal
insufficiency were included in a study where the
patients received one of three different doses of pros-
taglandin E-1 (10, 20, or 40 ng/kg body weight/min)
or placebo intravenously over a time period of 6 h
beginning 1 h prior to radiocontrast application. In
the placebo group, the mean elevation of S-creatinine
was markedly higher after the contrast infusion than
those receiving prostaglandin-E-1. However, no
clinically relevant changes were seen regarding the
creatinine clearance.52 Thus, the results are promising
but randomised studies with clinical important
outcomes are needed.
Dopamine
Low-dose dopamine has a dilatory effect on the renal
vascular musculature, but the effect of dopamine on
renal blood flow in patients with chronic renal insuf-
ficiency is controversial.24,33 In a randomised con-
trolled trial, 66 patients with prior renal insufficiency
and/or diabetes mellitus were randomised to either
120 ml/dayof0.9%salineplusdopamine2 mg/kg/min
(Dopamine group) or saline alone (Control group) for
24 h before and after examination. There was no sig-
nificant difference in the change of creatinine between
the two groups. However, subgroup analysis revealed
that patients with peripheral vascular disease had a
significantly higher increase in S-creatinine after the
use of dopamine compared with controls.53
In another randomised trial, patients with prior
renal insufficiency were hydrated with 0.45% NaCl
intravenously at 100 ml/h for 12 h and then rando-
mised to either 0.45% NaCl intravenously at 100 ml/h
or dopamine intravenously at 2 mg/kg/min for 2 h
during and after cardiac catheterisation. CN was
defined as a 25% increase of S-creatinine above base-
line 48 h after radiological examination. The frequency
of CN was not different between the two groups
but dopamine infusion was associated with a sig-
nificant increase in renal blood flow throughout
the examination.54
In a third trial, 50 patients with prior renal insuffi-
ciency were randomised to receive either isotonic
saline, or one of three renal vasodilator/diuretic
drugs: dopamine, atrial natriuretic peptide (ANP), or
mannitol by intravenous infusion. Diabetic patients
exposed to one of the three drugs had the greatest
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increase in renal blood flow. The incidence of CN
among the diabetics receiving those drugs was 83, 83
and 75%, in the dopamine, ANP and mannitol groups,
respectively. In contrast, among the nondiabetics in
each of those groups the incidence of CN was zero.
In the saline control group, CN in the diabetics and
nondiabetics were 43 and 38%, respectively. The find-
ings were non-significant and the power of the study
could be discussed: 50 patients to four groups. Never-
theless, in summary of the three trials, dopamine
could seem to increase the renal blood flow but it
does not provide protection against CN.55
Calcium-antagonists
One hundred and twenty one outpatients with normal
renal function received a single dose of placebo or
nitrendipine 10 or 20 mg nitrendipine perorally 1 h
before the procedure. S-creatinine and U-albumin
remained unchanged.17
In another study, 27 patients (15 diabetics and 12
non-diabetics) with normal to moderately reduced
renal function were randomised to hydration or hydra-
tion combined with 10 mg oral felodipine (Plendil)
3±4 h before angiography. S-creatinine increased
significantly in the felodipine group but not in the
placebo group.56
In a third study, 42 patients were randomised to
receive nifedipine 10 mg orally 1 h before examination
or no treatment. The mean changes in S-creatinine
were insignificant. In a fourth randomised study, 35
patients were randomised to a 3-day treatment with
20 mg nitrendipine daily starting 1 day before X-ray
examination or placebo. Despite the fact that baseline
renal function was significantly more compromised in
the investigational group, the prophylactic application
of nitrendipine preserved the glomerular filtration
rate, whereas control patients showed a significant
(27%) reduction in GFR on day 2 after contrast-
media injection (p less than or equal to 0.01).
Moreover, the increase in proteinuria and specific
enzymuria was ameliorated by nitrendipine.57
Thus, calcium channel antagonists may protect
against CN, but the treatment apparently needs to be
started the day before, and continued two days after
exposure. However, the results seem needed to be con-
firmed in other studies using clinical important acute
renal failure as end-point and a larger sample size.
Angiotensin converting enzyme inhibitors
Pharmacological inhibition of angiotensin II using
either angiotensin converting enzyme (ACE) inhibi-
tors or more recently angiotensin receptor II antago-
nists have been shown to be effective in the treatment
and prophylaxis of experimental CN.58
Antioxidants
N-acetylcysteine (NAC), the acetylated variant of the
amino acid L-cysteine, is an excellent source of sulfhy-
dryl groups, and is converted in the body into meta-
bolites capable of stimulating glutathione synthesis,
promoting detoxification, and acting directly as free
radical scavengers.59±62
Besides, the scavenging effect, NAC could also pro-
tect by inhibiting ACE, which has been shown to be
involved in experimental CN (see above). In a com-
bined animal and human study, conscious rats
received NAC or placebo infusion. After 2 h of infu-
sion, the ACE activity was reduced with 31%. In a
following human study, isosorbide dinitrate (5 mg/h)
was infused into six male volunteers for 48 h followed
by NAC (2 g i.v. followed by 5 mg/kg/h) from 24 to
48 h. p-angiotensin II increased during the first 24 h
and 2 h after NAC infusion (p50.05). The results sug-
gest that sulfhydryl supplementation modifies
the function of the renin/angiotensin system in vivo,
an effect probably mediated by inhibition of ACE
activity.63
Finally, a randomised clinical trial of NAC versus
placebo concerning CN have been reported; 83 patients
with chronic renal insufficiency, who were under-
going computed tomography and had a nonionic,
low-osmolality contrast agent, were randomly
assigned either to receive NAC (600 mg orally twice
daily) and 0.45% saline intravenously, before and after
exposure, or to receive placebo and saline. Two percent
in the acetylcysteine group versus 21% in the placebo
group had an increase of at least 44 mmol/l in
S-creatinine 48 h after exposure (p 0.01). In the
acetylcysteine group, the mean S-creatinine decreased
significantly (p50.001), whereas in the control group,
the mean S-creatinine increased nonsignificantly
(p 0.18).
Consequently, the results of this well-conducted
study suggest that simple oral administration of
acetylcysteine along with hydration prevents CN in
patients with prior renal insufficiency.64 The weakness
of the study seems to be that clinical important CN
was not an end point.
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